Annual EBIT
-$207.88 M
-$80.84 M-63.63%
December 31, 2023
Summary
- As of February 8, 2025, INBX annual earnings before interest & taxes is -$207.88 million, with the most recent change of -$80.84 million (-63.63%) on December 31, 2023.
- During the last 3 years, INBX annual EBIT has fallen by -$143.07 million (-220.72%).
- INBX annual EBIT is now -955.03% below its all-time high of -$19.70 million, reached on December 31, 2017.
Performance
INBX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$43.86 M
-$1.91 B-102.35%
September 30, 2024
Summary
- As of February 8, 2025, INBX quarterly earnings before interest & taxes is -$43.86 million, with the most recent change of -$1.91 billion (-102.35%) on September 30, 2024.
- Over the past year, INBX quarterly EBIT has dropped by -$1.91 billion (-102.35%).
- INBX quarterly EBIT is now -102.35% below its all-time high of $1.86 billion, reached on June 30, 2024.
Performance
INBX Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
$1.74 B
-$226.00 K-0.01%
September 30, 2024
Summary
- As of February 8, 2025, INBX TTM earnings before interest & taxes is $1.74 billion, with the most recent change of -$226.00 thousand (-0.01%) on September 30, 2024.
- Over the past year, INBX TTM EBIT has dropped by -$226.00 thousand (-0.01%).
- INBX TTM EBIT is now -0.01% below its all-time high of $1.74 billion, reached on June 30, 2024.
Performance
INBX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
INBX EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -63.6% | -102.3% | -0.0% |
| 3 y3 years | -220.7% | -10.9% | +1365.3% |
| 5 y5 years | -606.0% | -10.9% | +1365.3% |
INBX EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -171.6% | at low | -102.3% | +10.9% | -0.0% | +1184.4% |
| 5 y | 5-year | -364.2% | at low | -102.3% | +10.9% | -0.0% | +1184.4% |
| alltime | all time | -955.0% | at low | -102.3% | +10.9% | -0.0% | +1184.4% |
Inhibrx Biosciences EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$43.86 M(-102.4%) | $1.74 B(-0.0%) |
| Jun 2024 | - | $1.86 B(-3886.3%) | $1.74 B(-1184.6%) |
| Mar 2024 | - | -$49.21 M(+72.0%) | -$160.61 M(+6.4%) |
| Dec 2023 | -$207.88 M(+63.6%) | -$28.61 M(-34.4%) | -$150.94 M(-3.3%) |
| Sep 2023 | - | -$43.64 M(+11.5%) | -$156.12 M(+9.7%) |
| Jun 2023 | - | -$39.14 M(-1.0%) | -$142.26 M(+3.4%) |
| Mar 2023 | - | -$39.54 M(+17.0%) | -$137.65 M(+8.3%) |
| Dec 2022 | -$127.04 M(+66.0%) | -$33.80 M(+13.5%) | -$127.09 M(+12.8%) |
| Sep 2022 | - | -$29.78 M(-13.8%) | -$112.69 M(+10.8%) |
| Jun 2022 | - | -$34.53 M(+19.1%) | -$101.72 M(+16.9%) |
| Mar 2022 | - | -$28.98 M(+49.3%) | -$86.99 M(+13.6%) |
| Dec 2021 | -$76.55 M | -$19.41 M(+3.2%) | -$76.55 M(+3.1%) |
| Sep 2021 | - | -$18.80 M(-5.0%) | -$74.25 M(+4.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | -$19.80 M(+6.8%) | -$71.03 M(+8.1%) |
| Mar 2021 | - | -$18.54 M(+8.3%) | -$65.72 M(+1.4%) |
| Dec 2020 | -$64.82 M(+44.7%) | -$17.11 M(+9.8%) | -$64.82 M(+5.1%) |
| Sep 2020 | - | -$15.58 M(+7.6%) | -$61.70 M(-1.6%) |
| Jun 2020 | - | -$14.48 M(-17.9%) | -$62.71 M(+6.6%) |
| Mar 2020 | - | -$17.64 M(+26.1%) | -$58.83 M(+31.4%) |
| Dec 2019 | -$44.78 M(+52.1%) | -$13.99 M(-15.7%) | -$44.78 M(+45.4%) |
| Sep 2019 | - | -$16.59 M(+56.6%) | -$30.79 M(+116.9%) |
| Jun 2019 | - | -$10.60 M(+194.4%) | -$14.20 M(+38.4%) |
| Mar 2019 | - | -$3.60 M(-46.0%) | -$10.26 M(-33.9%) |
| Dec 2018 | -$29.45 M(+49.4%) | - | - |
| Jun 2018 | - | -$6.66 M(-24.9%) | -$15.53 M(+75.1%) |
| Mar 2018 | - | -$8.87 M | -$8.87 M |
| Dec 2017 | -$19.70 M | - | - |
FAQ
- What is Inhibrx Biosciences annual earnings before interest & taxes?
- What is the all time high annual EBIT for Inhibrx Biosciences?
- What is Inhibrx Biosciences annual EBIT year-on-year change?
- What is Inhibrx Biosciences quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Inhibrx Biosciences?
- What is Inhibrx Biosciences quarterly EBIT year-on-year change?
- What is Inhibrx Biosciences TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Inhibrx Biosciences?
- What is Inhibrx Biosciences TTM EBIT year-on-year change?
What is Inhibrx Biosciences annual earnings before interest & taxes?
The current annual EBIT of INBX is -$207.88 M
What is the all time high annual EBIT for Inhibrx Biosciences?
Inhibrx Biosciences all-time high annual earnings before interest & taxes is -$19.70 M
What is Inhibrx Biosciences annual EBIT year-on-year change?
Over the past year, INBX annual earnings before interest & taxes has changed by -$80.84 M (-63.63%)
What is Inhibrx Biosciences quarterly earnings before interest & taxes?
The current quarterly EBIT of INBX is -$43.86 M
What is the all time high quarterly EBIT for Inhibrx Biosciences?
Inhibrx Biosciences all-time high quarterly earnings before interest & taxes is $1.86 B
What is Inhibrx Biosciences quarterly EBIT year-on-year change?
Over the past year, INBX quarterly earnings before interest & taxes has changed by -$1.91 B (-102.35%)
What is Inhibrx Biosciences TTM earnings before interest & taxes?
The current TTM EBIT of INBX is $1.74 B
What is the all time high TTM EBIT for Inhibrx Biosciences?
Inhibrx Biosciences all-time high TTM earnings before interest & taxes is $1.74 B
What is Inhibrx Biosciences TTM EBIT year-on-year change?
Over the past year, INBX TTM earnings before interest & taxes has changed by -$226.00 K (-0.01%)